Lec 12 | MIT 3.091 Introduction to Solid State Chemistry
Metallic Bonding, Band Theory of Solids (Heitler and London), Band Gaps in Metals, Semiconductors, and Insulators, Absorption Edge of a ...
Written by BioMedReports.com Staff
Cubist Pharmaceuticals, Inc.(NASDAQ: CBST), a leading acute care therapeutics company, today after the market close announced that the recently-completed Phase 2 study of CXA-101, a novel cephalosporin, compared to ceftazidime for the treatment of complicated urinary tract infections (cUTI) in adults met its study objectives. Cubist is developing CXA-201 as a first-line intravenous therapy for the treatment of serious Gram-negative bacterial infections in the hospital, including those caused by multi-drug resistant Pseudomonas aeruginosa. CXA-201 is a combination of CXA-101 and the beta-lactamase inhibitor tazobactam. Cubist acquired rights to CXA-101, and products which incorporate CXA-101, through its purchase of Calixa Therapeutics Inc. in December 2009.
The study met its objectives of assessing safety and efficacy of CXA-101 in comparison to ceftazidime. CXA-101 additionally demonstrated favorable microbiological and clinical outcomes at the Test of Cure Visit, 6 – 9 days after end of therapy, which were the primary and secondary outcome measures in this study, respectively.
High Potency HCl - News
|
StockProfiler.US: Pharmaceutical Stock Picks on the Move: Axxess Pharma, Inc ... Axxess Pharma, Inc. Signs Exclusive License Agreement to Globally Market and Distribute High Potency Vitamin D-3 to Help Reduce Bone Loss and Joint Pain |
